Clinical Trial

Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors

Study acronym: YK1101
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 24, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.
Trial Details
NCT Number NCT07139067
Lead Sponsor Peking University
Collaborators: Yingkai Saiwei（Beijing）Biotechnology Co., Ltd
Conditions Advanced Solid Tumor Cancer
Enrollment 10 participants
Start Date 2025-04-27
Primary Completion 2026-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-24